N-SMase

By Targets:	Apoptosis (2) Autophagy (3) Bacterial (5) Farnesyl Transferase (1) Isotope-Labeled Compounds (1) Phospholipase (11) Proton Pump (7) Ras (1) Sirtuin (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (1)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-131002

DPTIP

Phospholipase Inflammation/Immunology

DPTIP is a potent brain penetrant neutral sphingomyelinase 2 (N-SMase 2) inhibitor (exosome inhibitor), with an IC₅₀ of 30 nM .

DPTIP	Phospholipase	Inflammation/Immunology
DPTIP is a potent brain penetrant *neutral sphingomyelinase 2 (N-SMase* 2) inhibitor (exosome inhibitor), with an IC₅₀** of 30 nM .

HY-13662

Lansoprazole 1 Publications Verification AG-1749	Proton Pump Bacterial Phospholipase	Inflammation/Immunology Cancer
Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-19363

GW4869 Maximum Cited Publications 133 Publications Verification	Phospholipase	Cardiovascular Disease Inflammation/Immunology
GW4869 is a noncompetitive neutral sphingomyelinase (N-SMase) inhibitor with an IC₅₀ of 1 μM. GW4869 is an inhibitor of exosome biogenesis/release .

HY-100732

Cambinol 1 Publications Verification	Sirtuin Apoptosis Phospholipase	Cancer
Cambinol is a SIRT1 and SIRT2 inhibitor with IC₅₀ values of 56 μM and 59 μM, respectively. Cambinol is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-155111

nSMase2-IN-1	Phospholipase	Neurological Disease
nSMase2-IN-1 is an orally active Neutral sphingomyelinase 2 (nSMase2) inhibitor with an IC₅₀ value of 0.13 ± 0.06 μM. nSMase2-IN-1 is metabolically stable in liver microsomes and orally available with a favorable brain-to-plasma ratio. nSMase2-IN-1 can be used for nervous system disease research .

HY-13662B

(R)-Lansoprazole 2 Publications Verification Dexlansoprazole	Proton Pump	Inflammation/Immunology
(R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-13662C

(S)-Lansoprazole Levolansoprazole	Proton Pump Phospholipase Bacterial	Inflammation/Immunology
(S)-Lansoprazole (Levolansoprazole) is an isoform of Lansoprazole (HY-13662), which is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-13662BS

(R)-Lansoprazole-d4 Dexlansoprazole-d₄	Isotope-Labeled Compounds Proton Pump	Inflammation/Immunology
(R)-Lansoprazole-d₄ is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

HY-B0113

Omeprazole 2 Publications Verification H 16868	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113A

Omeprazole sodium 2 Publications Verification H 16868 sodium
Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S1

Omeprazole-d3-1 H 16868-d₃-1	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-B0113S3

Omeprazole-13CD3 H 16868-¹³C,d₃	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-149025

DPTIP-prodrug 18 P18	Phospholipase	Inflammation/Immunology
DPTIP-proagent 18 (P18) is a orally active and brain-penetrable proagent of DPTIP (HY-131002). DPTIP-proagent 18 is a potent *nSMase2* inhibitor. DPTIP-proagent 18 significantly inhibits IL-1β-induced EV (extracellular vesicle) release by inhibition of nSMase2 (neutral sphingomyelinase-2) activity. DPTIP-proagent 18 can be used for brain injury research .

HY-N6796

Manumycin A	Farnesyl Transferase Ras Apoptosis Phospholipase	Infection Cancer
Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling . Manumycin A is a *nSMase* inhibitor (EC₅₀=0.25 μM) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6796

Manumycin A	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Farnesyl Transferase Ras Apoptosis Phospholipase
Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling . Manumycin A is a *nSMase* inhibitor (EC₅₀=0.25 μM) .

Cat. No.	Compare	Product Name	Species	Source

HY-P702447

	SMPD2 Protein, Human (Cell-Free, His) Sphingomyelin phosphodiesterase 2; Lyso-platelet-activating factor-phospholipase C; Lyso-PAF-PLC; Neutral sphingomyelinase; N-SMase; nSMase; nSMase1	Human	E. coli Cell-free
	In vitro experiments have demonstrated that the sphingomyelin phosphodiesterase 2 (SMPD2) protein plays a key role in catalyzing the hydrolysis of sphingomyelin, leading to the formation of ceramide and phosphocholine. Furthermore, SMPD2 exhibits its enzymatic activity by hydrolyzing 1-O-alkyl-2-lyso-sn-glycero-3-phosphocholine (hemolytic platelet-activating factor) in vivo. SMPD2 Protein, Human (Cell-Free, His) is the recombinant human-derived SMPD2 protein, expressed by E. coli Cell-free , with N-10*His labeled tag. The total length of SMPD2 Protein, Human (Cell-Free, His) is 423 a.a., with molecular weight of 49.1 kDa.


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-13662BS

(R)-Lansoprazole-d4
(R)-Lansoprazole-d₄ is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

HY-B0113S1

Omeprazole-d3-1
Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-B0113S3

Omeprazole-13CD3
Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

Omeprazole-13CD3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds